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ESSENTIALS 
 The RIETE score was derived to predict 10-day adverse outcomes in acute pulmonary 
embolism (PE). 
 We externally validated the RIETE score in a prospective cohort of patients with PE. 
 The RIETE score classified fewer patients as low-risk than currently recommended 
scores. 
 The RIETE score was not superior to other scores in predicting 10-day adverse 
outcomes. 
 
SUMMARY 
Introduction: The RIETE score was derived to identify patients with pulmonary embolism 
(PE) at low risk of overall complications.  
Objective: To externally validated the RIETE score and compared its prognostic 
performance to the Pulmonary Embolism Severity Index (PESI), its simplified version 
(sPESI), and the Geneva Prognostic Score (GPS). 
Methods: In a prospective multicenter cohort, we studied 687 elderly patients with acute PE. 
The primary outcome was 10-day overall complications (death, recurrent PE, or major 
bleeding), the secondary outcome was 30-day overall mortality. We compared complications 
and mortality in low- vs. higher-risk patients and the area under the receiver operating 
characteristic (ROC) curve across scores. 
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Results: Overall, 27 patients (3.9%) had complications within 10 days and 22 (3.2%) died 
within 30 days. The RIETE score classified a smaller proportion of patients as low-risk (31%) 
than the PESI (35%), sPESI (36%), and the GPS (90%). The proportion of low-risk patients 
based on the RIETE score, PESI, sPESI, and GPS who had complications was 1.9%, 1.7%, 
1.6%, and 2.9%, respectively. The RIETE score had a lower area under the ROC curve 
(0.60) for predicting complications than the PESI (0.67), sPESI (0.65), and GPS (0.72). The 
area under the ROC curve for predicting mortality was similar (0.76-0.78) for all scores. 
Conclusion: The RIETE score classified fewer patients as low-risk than the other scores. It 
accurately identified patients at low mortality risk but was not superior to other scores in 
predicting 10-day overall complications. 
 
INTRODUCTION 
Determination of prognosis in patients with acute pulmonary embolism (PE) is a 
challenging task. Several clinical scores have been developed to help physicians estimate 
patients’ prognosis and identify potential candidates for home care (Table 1) [1-4]. The best-
validated clinical prognostic score for PE is the Pulmonary Embolism Severity Index (PESI) 
[1]. The PESI comprises 11 easily available variables and assigns patients into five risk 
classes of increasing risk of 30-day mortality. Patients in risk classes I and II have a low risk 
of 30-day mortality (2.2%) and are candidates for less costly outpatient care [5]. A simplified 
6-item version of the PESI (sPESI) is also available [2]. Patients with a point score of 0 are 
considered low risk and have a 30-day mortality of 1%. The Geneva Prognostic Score (GPS) 
consists of six clinical, laboratory, and radiologic variables [3]. Patients with a score of ≤2 
points have a low risk (2.2%) of a combined adverse outcome of death, recurrent venous 
thromboembolism (VTE), and major bleeding within 90 days [3]. 
Recently, a novel prognostic score for PE, the Registro Informatizado de la 
Enfermedad TromboEmbolica (RIETE) score, has been developed [4]. Patients without any 
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of nine clinical and laboratory factors have a low risk (<1%) of a combined adverse outcome 
of death, recurrent PE, or major bleeding within 10 days of the index event. While the RIETE 
score had a higher discriminative power than the PESI and the sPESI for predicting the 
combined adverse outcome in the derivation study (c statistic 0.77 vs. 0.72 and 0.71, 
respectively), the RIETE score has not been externally validated to date. Furthermore, 
prediction models usually perform better than existing scores when validation is done using 
the derivation sample [6,7]. 
 
We therefore aimed to externally validate the RIETE score and to directly compare its 
prognostic performance to the PESI, sPESI, and GPS in a prospective multicenter cohort of 
elderly patients with acute PE. 
 
METHODS 
Study sample 
The study was performed between September 2009 and December 2013 as part of 
the SWiss venous Thromboembolism COhort (SWITCO65+), a prospective multicenter 
cohort study that assessed long-term medical outcomes in elderly patients with acute 
symptomatic VTE from nine Swiss university and non-university hospitals [8]. Consecutive 
patients aged 65 years or older with objectively diagnosed symptomatic VTE were identified 
in the in- and outpatient services of all participating study sites. In this study, we considered 
only patients with an objectively diagnosed acute PE (n=687). The criteria used to establish 
the diagnosis of PE were a positive spiral computed tomography or pulmonary angiography, 
a high-probability ventilation-perfusion scan or a proximal deep vein thrombosis (DVT) 
documented by compression ultrasonography or contrast venography in patients with acute 
chest pain, new or worsening dyspnea, hemoptysis, or syncope [9]. 
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Patients with catheter-related thrombosis, insufficient German or French-speaking 
ability, conditions incompatible with the follow-up (i.e., terminal illness or place of living too 
far away from the study center), the inability to provide informed consent (i.e., severe 
dementia) or previously enrolled in the cohort were excluded. The ethics committee at each 
participating center approved the study. All participants gave their informed consent. A 
detailed description of the study methods has been published previously [8]. 
Baseline data collection 
For all enrolled patients, baseline demographic information (age and sex) and clinical 
data were prospectively collected by medical record review by trained research nurses and 
recorded on standard data collection forms. The comorbid conditions (active cancer, heart 
failure, chronic lung disease and recent major bleeding), vital parameters (mental status, 
heart rate, systolic blood pressure, respiratory rate, temperature and arterial oxygen 
saturation), laboratory findings (platelet count and creatinine clearance), and imaging results 
(proximal DVT by compression ultrasonography or contrast venography) that constitute the 
RIETE score, PESI, sPESI, and the GPS were abstracted as part of the medical record 
review. For all vital signs, the measurement most closely related in time to the 
diagnosis of PE was abstracted from patient charts. 
 
Clinical prognostic scores 
Based on patient demographics and baseline clinical data obtained by chart 
review, we calculated the RIETE score, PESI, sPESI, and the GPS for each patient. 
For the RIETE score, creatinine clearance was calculated using the Cockcroft and 
Gault formula [10]. We used “patients being confined to bed for >72 hours in the last 
3 months” as a proxy variable for recent immobility, originally defined as nonsurgical 
patients who were confined to bed with bathroom privileges for >4 days in the 2 
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months before PE diagnosis [4]. Furthermore, we used “major bleeding occurred 
during last 3 months” as a proxy variable for recent major bleeding, originally defined 
as major bleeding <30 days before PE [4]. For the GPS, we used an oxygen 
saturation <90% measured by pulse oximetry as a surrogate marker for a PaO2 <8 
kPa [3]. Finally, concomitant DVT was defined as asymptomatic or symptomatic 
proximal DVT diagnosed by ultrasound in the GPS derivation/validation study [3,11], 
whereas we used objectively confirmed symptomatic proximal DVT to define DVT. 
Based on commonly accepted definitions, patients with a RIETE score <1, 
PESI score ≤85 (risk classes I and II), sPESI score <1, and a GPS score ≤2 were 
considered at low risk of adverse outcomes [1-4]. All other patients were considered 
at higher risk of complications. Missing values were assumed to be normal, a 
strategy frequently used in the clinical application of clinical prognostic rules [1,12]. 
In a sensitivity analysis, we assumed missing variables to be abnormal. 
 
Study outcomes 
The primary outcome was overall complications within 10 days, defined as overall 
mortality, recurrent PE, or major bleeding. Secondary outcomes were 30-day overall 
mortality after the diagnosis of PE and overall complications at 90 days. Recurrent PE was 
defined as a new intraluminal filling defect on spiral computed tomography or pulmonary 
angiography, a cut-off of a vessel >2.5 mm in diameter on pulmonary angiography, a new 
perfusion defect involving 75% of a lung segment with corresponding normal ventilation 
(i.e., high probability lung scan) or confirmation of a new PE on autopsy [1,13]. 
We defined major bleeding according to the definition of the International Society of 
Thrombosis and Haemostasis as a fatal bleeding, a symptomatic bleeding at critical sites 
(intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial or 
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intramuscular with compartment syndrome), a bleeding with a reduction of hemoglobin ≥20 
g/L or a bleeding leading to the transfusion of 2 units or more of packed red blood cells [14]. 
We assessed outcomes using patient or proxy interviews, interview of the patient’s 
primary care physician, and/or hospital chart review. A committee of three blinded, 
independent clinical experts adjudicated all outcomes and classified the cause of death. 
Death was judged to be a definite fatal PE if it was confirmed by autopsy or if death followed 
a clinically severe PE, either initially or after an objectively confirmed recurrent event. Death 
in a patient who died suddenly or unexpectedly was classified as possible fatal PE. Final 
classification was made on the basis of the full consensus of the committee. 
 
Statistical analyses 
We performed pairwise comparisons of the proportion of patients classified as low-
risk by the four scores using McNemar’s test and adjusted P-values using the Bonferroni 
correction. We described the proportion of 10-day and 90-day overall complications (overall 
mortality, recurrent PE, or major bleeding), and overall 30-day mortality in low- versus 
higher-risk patients for each score and in patients stratified by the RIETE score as a 
continuous quantitative risk scale. To determine the accuracy of each score to predict 10-
day and 90-day overall complications, and 30-day overall mortality, we estimated sensitivity, 
specificity, positive and negative predictive values, and likelihood ratios for higher- versus 
low-risk patients. We assessed the discriminative power of each score to predict 10-day and 
90-day overall complications, and 30-day overall mortality by calculating the area under the 
receiver operating characteristic (ROC) curve. We performed a non-parametric test of the 
equality of the areas under the four curves. We determined the goodness-of-fit of the score 
points for 10-day and 90-day overall complications, and 30-day mortality in a logistic 
regression model using the Pearson chi-square test. 
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All analyses were done using Stata 14 (Stata Corporation, College Station, Texas). 
RESULTS 
Study sample 
Of the 695 identified patients with an objectively confirmed acute PE who were 
initially enrolled in SWITCO65+, we excluded 7 who refused the use of their data and 1 who 
withdrew from the study within 1 day of enrolment, leaving a final study sample of 687 
patients with acute PE. The baseline characteristics are shown in Table 2. 
 
Comparison of outcomes 
Overall, 12 patients (1.8 %; 95% confidence interval [CI], 1.0-3.0%), 22 patients 
(3.2%; 95% CI, 2.1-4.8%), and 39 patients (5.7%; 95% CI, 4.2-7.7%) died within 10, 30, and 
90 days, respectively. Seventeen patients (2.5%; 95% CI, 1.6-3.9%) suffered a major 
bleeding and one patient (0.2%; 95% CI, 0.0-0.8%) had a recurrent PE within 10 days. 
Thirty-eight patients (5.5%; 95% CI, 4.1-7.5%) suffered a major bleeding and six patients 
(0.9%; 95% CI, 0.4-1.9%) had a recurrent PE within 90 days. The RIETE score classified a 
smaller proportion of patients as low-risk (31% [215/687]) than the PESI (35% [238/687]; 
P<0.001), sPESI (36% [246/687]; P<0.001), and the GPS (90% [615/687]; P<0.001). 
The 10-day overall complications among low-risk patients were 1.9% (95% CI, 0.7-
4.7%) for the RIETE score, 1.7% (95% CI, 0.7-4.2%) for the PESI, 1.6% (95% CI, 0.6-4.1%) 
for the sPESI, and 2.9% (95% CI, 1.9-4.6%) for the GPS (Table 3). At 90 days, overall 
complications among low-risk patients were 3.7% (95% CI, 1.9-7.2%) for the RIETE score, 
3.8% (95% CI, 2.0-7.0%) for the PESI, 3.7% (95% CI, 1.9-6.8%) for the sPESI, and 8.3% 
(95% CI, 6.4-10.7%) for the GPS (Table 3). 
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Patients classified as low-risk based on the RIETE score, PESI, and sPESI had a 
very low 30-day overall mortality of 0.0% (95% CI, 0.0-1.8%), 0.4% (95% CI, 0.1%-2.3%), 
and 0.0% (95% CI, 0.0-1.5%), respectively, whereas low-risk patients based on the GPS had 
a higher 30-day mortality of 2.0% (95% CI, 1.1-3.4%) (Table 3). Overall, 30-day mortality 
was highest in higher-risk patients based on the GPS (13.9%; 95% CI, 7.7-23.7%) and 
lowest in higher-risk patients based on the RIETE score (4.7%; 95% CI, 3.1-7.0%). PE-
related 30-day mortality was 0.0% among low-risk patients based on the RIETE score, PESI, 
and sPESI, and 0.5% (95% CI, 0.2-1.4%) among low-risk patients based on the GPS. 
When using the RIETE score as a continuous quantitative risk scale, complications 
within 10 days occurred in 1.9% (95% CI, 0.7-4.7%), 4.8% (95% CI, 2.6-8.6%), 3.2% (95% 
CI, 1.3-7.9%), 6.9% (95% CI, 3.0-15.3%), and 6.1% (95% CI, 2.4-14.6%) of patients with a 
point score of 0, 1, 2, 3, and ≥4, respectively (Table 4). 
 
Comparison of predictive accuracy and discriminative power 
All four scores were less accurate in predicting overall complications than in 
predicting mortality, especially at 10 days (Table 5). The RIETE score, the PESI and the 
sPESI had all a sensitivity of 85% for predicting 10-day overall complications, whereas the 
GPS had a sensitivity of only 33% (Table 5). The positive predictive values for 10-day overall 
complications were low (<13%) and the negative predictive values were high (≥97%) for all 
scores (Table 5). The positive and negative likelihood ratios were generally poor except for 
the positive likelihood ratio of the GPS (3.49). While the areas under the ROC curve for 
predicting 10-day overall complications varied from 0.60 for the RIETE score to 0.72 for the 
GPS (Figure 1, Panel A), the areas under the ROC curve for predicting 90-day overall 
complications were similar for all scores (0.68-0.70) (Figure 1, Panel B).  
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The RIETE score and the sPESI had both a sensitivity of 100% for predicting 30-day 
overall mortality, whereas the PESI had a sensitivity of 96% and the GPS a sensitivity of only 
46% (Table 5). As for overall complications, the positive predictive values for 30-day 
mortality were low (<14%) and the negative predictive values were high (≥98%) for all scores 
(Table 5). The RIETE score, PESI, and the sPESI showed a good negative likelihood ratio of 
0.07 (95% CI, 0-1.04), 0.13 (95% CI, 0.02-0.87), and 0.06 (95% CI, 0-0.91), respectively, 
whereas the GPS had a poor negative likelihood ratio of 0.60 (95% CI, 0.41-0.88). The 
positive likelihood ratios were generally poor except for the GPS (4.88). The discriminative 
power for predicting 30-day overall mortality was good (area under the ROC curve 0.76-
0.78) and did not significantly differ between the scores (P=0.87) (Figure 1, Panel C). 
The goodness-of-fit was adequate for all scores. When we assumed missing 
variables to be abnormal in a sensitivity analysis, the area under the ROC curve for 
predicting 30-day overall mortality and overall complications remained similar across all 
scores. 
 
DISCUSSION 
In our prospective multicenter cohort of elderly patients with acute PE, the RIETE and 
both PESI scores accurately identified patients at low risk of 30-day overall mortality, 
whereas the GPS was less accurate in identifying low-risk patients. All scores were less 
accurate in predicting overall complications, especially at 10 days. The RIETE score 
classified a lower proportion of patients as low-risk than the other scores and had a 
somewhat lower discriminative power for 10-day complications, the outcome for which it was 
derived. 
In contrast to the PESI and the sPESI, which were derived as mortality prediction 
scores, the RIETE score was developed to predict 10-day overall complications because 
“clinical care should be based on a broader set of medical outcomes than just mortality” [4]. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
It also has been argued that outcomes within 7 to 10 days may be more relevant to the 
hospital admission decision than outcomes within longer follow-up durations [15]. In the 
RIETE derivation study, the RIETE score had a statistically significantly better discriminative 
power for predicting 10-day overall complications than the PESI or the sPESI (area under 
the ROC curve 0.77 vs. 0.72 and 0.71, respectively) [4]. Even though the RIETE score was 
specifically derived to predict 10-day overall complications, it had a lower area under the 
ROC curve (0.60) for predicting complications at 10 days than the PESI (0.67), sPESI (0.65), 
and GPS (0.72) in our sample. Of note, in the RIETE score derivation study only patients 
with a PESI risk class I were considered low-risk [4], whereas in the PESI derivation and 
validation studies patients with risk classes I and II were considered at low risk [1,5]. 
Although the patients included in the RIETE derivation sample were younger than in 
our sample (mean age 67 years vs. median age of 75 years), they had a similar prevalence 
of cancer, chronic heart failure and lung disease, moderate to severe kidney impairment, 
and an abnormal platelet count, and a higher prevalence of tachycardia, hypotension, 
hypoxemia, immobility, and concurrent DVT [4]. The 10-day overall complications rate was 
both 3.9% in the RIETE sample and our study. Overall, our results confirm that a novel 
prediction model must prove its predictive performance in different patient populations and 
over different disease spectrums before its use can be recommended [16]. Among the 
clinical scores evaluated in our study, the PESI remains the only clinical prognostic model for 
acute PE whose effectiveness and safety has been successfully validated in a randomized-
controlled trial [5]. The safety and efficacy of the sPESI and the Hestia criteria are currently 
evaluated in an ongoing multinational open-label randomized controlled trial 
(clinicaltrials.gov, identifier: NCT02811237). 
As the RIETE score and the PESI both consist of 11 variables that are widely 
available at admission, there may not be any difference in user-friendliness between the 
scores. The GPS, which requires venous ultrasonography and arterial blood gas analysis, is 
more difficult to use. 
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Our study has potential limitations. First, we used immobility and major bleeding 
within 3 months as proxy measures for recent immobility and major bleeding, which may 
have overestimated disease severity and decreased the prognostic performance of the 
RIETE score. Conversely, the fact that we included only symptomatic proximal DVT and not 
all proximal DVTs may have decreased disease severity as determined by the GPS. 
Second, for calculation of the four scores, missing variables were considered to be normal. 
However, the prevalence of missing values was low and when we assumed missing values 
to be abnormal, the results remained similar, confirming the robustness of our results. Third, 
because the model coefficients and intercept were not reported in the derivation study [4], 
we could not calibrate the model. Finally, we have not done a specific a priori power 
calculation for this ancillary study of SWITCO65+. Thus, our study may not have sufficient 
power to compare the scores’ discriminative power, especially for the prediction of 10-day 
overall complications. 
In conclusion, we externally validated the RIETE score in elderly patients with acute 
PE. The RIETE score had a similar discriminative power to predict 30-day mortality than 
both PESI scores. All scores were less accurate in identifying patients at low risk of overall 
complications. As the RIETE score had a somewhat lower discriminative power for 10-day 
complications and classified a lower proportion of patients as low-risk than the other scores, 
it may not offer a practical advantage over the PESI and sPESI. 
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ADDENDUM 
E. Jaquet, T. Tritschler, O. Stalder, A. Limacher, and D. Aujesky were responsible for study 
concept and design. O. Stalder and A. Limacher did the statistical analyses. E. Jaquet, T. 
Tritschler, and D. Aujesky wrote the manuscript. A. Limacher, M. Méan, and N. Rodondi 
revised the manuscript. N. Rodondi and D. Aujesky collected data and obtained funding from 
the Swiss National Science Foundation. 
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LEGENDS TO FIGURES 
Figure 1. 
Panel A. Receiver-operating characteristic curve for 10-day overall complications 
The areas under the ROC curves were 0.60 (95% CI 0.57-0.64) for the RIETE score, 0.67 
(95% CI 0.64-0.71) for the PESI, 0.65 (95%CI 0.62-0.69) for the sPESI, and 0.72 (95% CI 
0.68-0.75) for the GPS (P=0.062). 
 
Panel B. Receiver-operating characteristic curve for 90-day overall complications 
The areas under the ROC curves were 0.70 (95% CI 0.66-0.73) for the RIETE score, 0.69 
(95% CI 0.66-0.73) for the PESI, 0.68 (95% CI 0.65-0.72) for the sPESI, and 0.69 (95% CI 
0.66-0.73) for the GPS (P=0.967). 
 
Panel C. Receiver-operating characteristic curve for 30-day overall mortality 
The areas under the ROC curves were 0.76 (95% CI 0.73-0.79) for the RIETE score, 0.78 
(95% CI 0.75-0.81) for the PESI, 0.78 (95%CI 0.75-0.81) for the sPESI, and 0.76 (95% CI 
0.72-0.79) for the GPS (P=0.865). 
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 
Table 1. Clinical prognostic scores for patients with acute pulmonary embolism 
RIETE score 
Points 
assigned†† 
 
 
Chronic heart failure +1   
Cancer without metastasis* +1   
Cancer with metastasis* +2   
Systolic blood pressure <100 mm Hg +1   
Oximeter oxygen saturation <90% +1   
Heart rate ≥110 beats/min. +1   
Creatinine clearance 30-60 ml/min. +1   
Creatinine clearance <30 ml/min. +3   
Recent major bleeding† +2   
Recent immobility ≥4 days‡ +1   
Platelet count <100,000/µl or >450,000/µl +1   
Pulmonary Embolism Severity Index 
Points 
assigned in 
original 
version‡‡ 
 
Points assigned 
in simplified 
version§§ 
Age +1 per year   +1 (age ≥80 years) 
Male sex +10  - 
Cancer +30  +1 
Heart failure +10  +1** 
Chronic lung disease +10  
Heart rate ≥100 beats/min. +20  +1 
Systolic blood pressure <100 mm Hg +30  +1 
Respiratory rate ≥30 breaths/min. +20  - 
Temperature <36°C +20  - 
Altered mental status§ +60  - 
Oximeter oxygen saturation <90%¶ +20  +1 
Geneva Prognostic Score 
Points 
assigned¶¶ 
 
 
Cancer +2   
Heart failure +1   
Previous deep vein thrombosis +1   
Systolic blood pressure <100 mm Hg +2   
PaO2 <8 kPa +1   
Concomitant deep vein thrombosis +1   
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* Newly diagnosed cancer or cancer that is being treated with surgery, 
chemotherapy, radiotherapy, or hormonal or supportive therapy. 
† During the last 30 days before PE. 
‡ Nonsurgical patients who were confined to bed with bathroom privileges for >4 
days in the two months before PE diagnosis. 
§ Disorientation, lethargy, stupor, or coma. 
¶ With or without the administration of supplemental oxygen. 
** The variables “heart failure” and “chronic lung disease” were combined into a 
single category of chronic cardiopulmonary disease. 
†† Overall point score is obtained by summing the points for every applicable 
predictor. Risk classes defined by overall point score: <1 point, low risk (10-day 
adverse outcome risk 0.6%); ≥1 points, higher risk (10-day adverse outcome risk 
4.6%). 
‡‡ Overall point score is obtained by summing the patient’s age in years and the 
points for every applicable predictor. Patients with ≤85 points (risk classes I and 
II), low risk (30-day mortality risk 2.2%); >85 points, higher risk (30-day mortality 
risk 14.0%). 
§§ Overall point score is obtained by summing the points for every applicable 
predictor. Risk classes defined by overall point score: 0 point, low risk (30-day 
mortality risk 1.0%); ≥1 points, higher risk (30-day mortality risk 10.9%). 
¶¶ Overall point score is obtained by summing the points for every applicable 
predictor. Risk classes defined by overall point score: ≤2 points, low risk (90-day 
adverse outcome risk 2.2%); ≥3 points, higher risk (90-day adverse outcome risk 
27.3%).  
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Table 2. Patient baseline characteristics (N=687) 
Characteristic* 
n (%) or median 
(interquartile range) 
Missing values 
n (%) 
Patient age, years 75.0 (70.0; 81.0) 0 (0) 
Age >80 years 185 (27) 0 (0) 
Female sex 327 (48) 0 (0) 
Chronic heart failure* 49 (7) 0 (0) 
Chronic or acute heart failure* 81 (12) 0 (0) 
Chronic lung disease† 104 (15) 0 (0) 
Chronic heart failure and lung disease combined*† 161 (23) 0 (0) 
Cancer without metastasis‡ 68 (10) 0 (0) 
Cancer with metastasis‡ 49 (7) 0 (0) 
Systolic blood pressure <100 mmHg 26 (4) 5 (1) 
Heart rate ≥110 beats per minute 81 (12) 5 (1) 
Respiratory rate ≥30 breaths per minute 29 (4) 140 (20) 
Oximeter oxygen saturation <90% 103 (15) 52 (8) 
Altered mental status§ 23 (3) 0 (0) 
Temperature <36°C 48 (7) 18 (3) 
Creatinine clearance 30-60 ml/min. 229 (33) 13 (2) 
Creatinine clearance <30 ml/min. 37 (5) 13 (2) 
Major bleeding occurred during last 3 months 33 (5) 1 (0) 
Recent immobility¶ 109 (16) 3 (0) 
Platelet count <100,000/µl or >450,000/µl 44 (6) 11 (2) 
Previous deep vein thrombosis 113 (16) 1 (0) 
Concomitant proximal deep vein thrombosis** 107 (16) 0 (0) 
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Localization of pulmonary embolism  34 (5) 
Central 221 (32)  
Lobar 149 (22)  
Segmental 217 (32)  
Subsegmental 66 (10)  
Score points   
RIETE score 1 (0; 2) 67 (10)†† 
Pulmonary Embolism Severity Index 94 (81; 113) 192 (28)†† 
Simplified Pulmonary Embolism Severity Index 1 (0; 2) 53 (8)†† 
Geneva Prognostic Score 1 (0; 2) 54 (8)†† 
* Systolic or diastolic heart failure, left or right heart failure, forward or backward heart failure, 
or a known left ventricular ejection fraction of <40%. 
† Chronic obstructive pulmonary disease, active asthma, lung fibrosis, cystic fibrosis, or 
bronchiectasis. 
‡ Cancer requiring surgery, chemotherapy, radiotherapy, or palliative care during the last 3 
months before index PE. 
§ Disorientation, lethargy, stupor, or coma. 
¶ Patients being confined to bed for >72 hours in the last 3 months. 
** Objectively confirmed, symptomatic proximal deep vein thrombosis. 
†† Patients with at least one missing score variable.  
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Table 3. Outcomes in low- vs. higher-risk patients 
 Low risk Higher risk All patients 
Outcome n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) 
10-day overall complications*   27/687 3.9 (2.7-5.7) 
  RIETE 4/215 1.9 (0.7-4.7) 23/472 4.9 (3.3-7.2)   
  PESI 4/238 1.7 (0.7-4.2) 23/449 5.1 (3.4-7.6)   
  sPESI 4/246 1.6 (0.6-4.1) 23/441 5.2 (3.5-7.7)   
  GPS 18/615 2.9 (1.9-4.6) 9/72 12.5 (6.7-22.1)   
30-day overall mortality   22/687 3.2 (2.1-4.8) 
  RIETE 0/215 0 (0-1.8) 22/472 4.7 (3.1-7.0)   
  PESI 1/238 0.4 (0.1-2.3) 21/449 4.7 (3.1-7.0)   
  sPESI 0/246 0 (0-1.5) 22/441 5.0 (3.3-7.4)   
  GPS 12/615 2.0 (1.1-3.4) 10/72 13.9 (7.7-23.7)   
30-day PE-related mortality   8/687 1.2 (0.6-2.3) 
  RIETE 0/215 0 (0-1.8) 8/472 1.7 (0.9-3.3)   
  PESI 0/238 0 (0-1.6) 8/449 1.8 (0.9-3.5)   
  sPESI 0/246 0 (0-1.5) 8/441 1.8 (0.9-3.5)   
  GPS 3/615 0.5 (0.2-1.4) 5/72 6.9 (3.0-15.3)   
90-day overall complications*   70/687 9.9 (7.9-12.4) 
  RIETE 8/215 3.7 (1.9-7.2) 60/472 12.7 (10.0-16.0)   
  PESI 9/238 3.8 (2.0-7.0) 59/449 13.1 (10.3-16.6)   
  sPESI 9/246 3.7 (1.9-6.8) 59/441 13.4 (10.5-16.9)   
  GPS 51/615 8.3 (6.4-10.7) 17/72 23.6 (15.3-34.6)   
Abbreviations: CI, confidence interval; PE, pulmonary embolism. 
* Defined as death, major bleeding or recurrent pulmonary embolism, whichever occurred 
first.  
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Table 4. Outcomes in patients stratified by the RIETE score as a continuous risk scale 
 
10-day overall 
complications* 
30-day overall 
mortality 
90-day overall 
complications* 
RIETE Score n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) 
0 points 4/215 1.9 (0.7-4.7) 0/215 0.0 (0.0-1.8) 8/215 3.7 (1.9-7.2) 
1 point 10/209 4.8 (2.6-8.6) 6/209 2.9 (1.3-6.1) 16/209 7.7 (4.8-12.1) 
2 points 4/125 3.2 (1.3-7.9) 4/125 3.2 (1.3-7.9) 13/125 10.4 (6.2-17.0) 
3 points 5/72 6.9 (3.0-15.3) 5/72 6.9 (3.0-15.3) 15/72 20.8 (13.1-31.6) 
≥4 points 4/66 6.1 (2.4-14.6) 7/66 10.6 (5.2-20.3) 16/66 24.2 (15.5-35.8) 
Abbreviations: CI, confidence interval. 
* Defined as death, major bleeding or recurrent pulmonary embolism, whichever occurred 
first. 
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Table 5. Measures of performance to predict overall mortality and complications 
Outcome Sensitivity, 
% (95% CI) 
Specificity, 
% (95% CI) 
PPV, %  
(95% CI) 
NPV, %  
(95% CI) 
Positive LHR 
(95% CI) 
Negative LHR 
(95% CI) 
Goodness 
of-fit† 
TP FN FP TN 
10-day overall 
complications* 
           
  RIETE 85 (68-94) 32 (29-36) 5 (3-7) 98 (95-99) 1.25 (1.06-1.48) 0.46 (0.19-1.15) 0.22 23 4 449 211 
  PESI 85 (68-94) 36 (32-39) 5 (3-8) 98 (96-99) 1.32 (1.12-1.56) 0.42 (0.17-1.04) 0.52 23 4 426 234 
  sPESI 85 (68-94) 37 (33-40) 5 (4-8) 98 (96-99) 1.35 (1.14-1.59) 0.40 (0.16-1.00) 0.72 23 4 418 242 
  GPS 33 (19-52) 91 (88-93) 13 (7-22) 97 (95-98) 3.49 (1.95-6.25) 0.74 (0.56-0.96) 0.79 9 18 63 597 
30-day overall 
mortality 
           
  RIETE 100 (85-100) 32 (29-36) 5 (3-7) 100 (98-100) 1.48 (1.40-1.56) 0.07 (0-1.04)‡ 0.11 22 0 450 215 
  PESI 96 (78-99) 36 (32-39) 5 (3-7) 100 (98-100) 1.48 (1.33-1.65) 0.13 (0.02-0.87) 0.10 21 1 428 237 
  sPESI 100 (85-100) 37 (33-41) 5 (3-7) 100 (99-100) 1.59 (1.50-1.68) 0.06 (0-0.91)‡ 0.17 22 0 419 246 
  GPS 46 (27-65) 91 (88-93) 14 (8-24) 98 (97-99) 4.88 (2.91-8.16) 0.60 (0.41-0.88) 0.23 10 12 62 603 
90-day overall 
complications* 
           
  RIETE 88 (79-94) 33 (30-37) 13 (10-16) 96 (93-98) 1.33 (1.20-1.47) 0.35 (0.18-0.68) 0.62 60 8 412 207 
  PESI 87 (77-93) 37 (33-41) 13 (10-17) 96 (93-98) 1.38 (1.23-1.54) 0.36 (0.19-0.66) 0.34 59 9 390 229 
  sPESI 87 (77-93) 38 (35-42) 13 (11-17) 96 (93-98) 1.41 (1.26-1.57) 0.35 (0.19-0.64) 0.21 59 9 382 237 
  GPS 25 (16-36) 91 (89-93) 24 (15-35) 92 (89-94) 2.81 (1.74-4.56) 0.82 (0.72-0.95) 0.04 17 51 55 564 
Abbreviations: CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; LHR, likelihood ratio; TP, true positive; 
FN, false negative; FP, false positive; TN, true negative. 
* Defined as death, major bleeding or recurrent pulmonary embolism, whichever occurred first. 
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† P-values from Pearson’s 2 goodness-of-fit test. P-values ≥0.05 indicate an adequate goodness of fit. 
‡ Computed using the continuity correction.  
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